Equities

Antibiotice SA

Antibiotice SA

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (RON)0.56
  • Today's Change-0.002 / -0.36%
  • Shares traded39.42k
  • 1 Year change22.81%
  • Beta0.3964
Data delayed at least 15 minutes, as of Apr 28 2017 12:11 BST.
More ▼

Profile data is unavailable for this security.

About the company

Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.

  • Revenue in RON (TTM)332.44m
  • Net income in RON30.37m
  • Incorporated1991
  • Employees1.45k
  • Location
    Antibiotice SAStr. Valea Lupului nr. 1IASI 707410RomaniaROU
  • Phone+40 232209000
  • Fax+40 232209633
  • Websitehttp://www.antibiotice.ro/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Diurnal Group PLC0.00-8.74m65.79m12.00--3.20-----0.1675-0.16750.000.39380.00----0.00-29.18---31.40-------------87.780.1409-------123.66------
Verona Pharma Plc0.00-5.02m68.31m7.00--1.98-----0.1526-0.15260.000.67110.00----0.00-18.59-39.44-24.30-47.28------------0.00------33.02--35.47--
ReNeuron Group Plc40.00k-14.57m69.62m44.00--1.15--1,740.54-0.0046-0.00460.000010.01910.0006--0.0494909.09-20.49-41.87-21.57-46.60-----36,422.50-28,913.04----0.00002---3.330.00-27.49--55.72--
ImmuPharma PLC65.77k-6.10m70.83m10.00--10.81--1,076.93-0.0601-0.06010.00070.05060.0108--0.03826,577.00-100.19-35.71-113.74-39.77-----9,270.87-6,349.88---12.980.0607---58.6618.68-35.73---23.41--
Abzena PLC15.31m-10.20m71.56m139.00--1.17--4.67-0.0803-0.08030.11860.28690.39316.863.12110,165.50-26.17---30.35--43.73---66.58--2.64--0.00--73.88---105.38------
Quantum Pharma PLC78.53m4.06m72.72m420.0014.080.966111.550.9260.03050.03050.60240.44510.736311.466.14186,973.803.81--5.16--33.63--5.17--0.59896.860.3457--13.41--704.02------
Motif Bio PLC0.00-16.08m74.67m4.00--3.54-----0.1637-0.16370.000.10760.00----0.00-119.43---182.30-------------64.180.2039-------618.17------
Oncodesign SA14.27m-303.39k88.64m102.00--7.70--6.21-0.0414-0.04142.111.690.79616.004.27---1.69-4.09-2.69-7.5531.7625.73-2.13-4.382.27--0.0582--102.0626.07152.55--44.11--
Abivax SA0.00-14.30m89.26m25.00---------1.48-1.480.00--------------------------------------10.37------
Asit Biotech SA-100.00bn-100.00bn89.30m19.00-------------------------------------------------100.00---59.94------
Pharnext SAS0.00-13.79m90.27m-----------2.69-2.690.00-4.90---------------------------2.9758.12-------2.45------
Antibiotice SA332.44m30.37m375.95m1.45k12.380.9197.741.130.04520.04520.49520.60930.61672.461.48229,423.805.635.697.187.6855.4967.179.149.182.4944.460.090560.060.71123.4911.748.50-4.4924.44
BioInvent International AB71.28m-62.59m734.32m51.00--3.19--10.30-0.2177-0.21770.27830.75630.431--4.151,397,726.00-37.85-72.79-48.16-113.90-----87.80-159.645.86--0.00--347.62-10.5730.98--1.60--
Oasmia Pharmaceutical AB186.00k-151.14m755.90m77.00--2.49--4,063.98-1.38-1.380.00172.550.0004-0.63720.03352,480.00-29.17-22.79-46.81-31.665,236.561,634.11-81,260.22-5,345.970.154-7.660.3522--207.87126.89-20.46---27.37--
Photocure ASA143.63m35.31m797.64m50.0022.633.1718.485.551.641.646.6411.690.5380.59724.172,872,540.0013.23-6.9315.03-7.8493.5093.4724.58-18.306.44--0.00--6.614.71197.6012.89-1.02--
Data as of Apr 28 2017. Currency figures normalised to Antibiotice SA's reporting currency: RON

Institutional shareholders

20.19%Per cent of shares held by top holders
HolderShares% Held
Oltenia SIF SA (Investment Management)as of 30 Jun 201690.98m13.55%
Transilvania SIF SA (Invt Mgmt)as of 31 Mar 201627.09m4.04%
Financial Investment Company Moldova SA (Invt Mgmt)as of 31 Mar 20163.29m0.49%
St. Galler Kantonalbank AG (Private Banking)as of 31 Dec 20162.66m0.40%
Parametric Portfolio Associates LLCas of 28 Feb 20172.42m0.36%
Erste Asset Management SAI SAas of 30 Jun 20162.36m0.35%
Danske Bank A/S (Investment Management)as of 28 Feb 20171.98m0.30%
BT Asset Management SAI SAas of 31 Dec 20161.90m0.28%
SAI Muntenia Invest SAas of 31 Mar 20161.77m0.26%
Globinvest SAI SAas of 30 Jun 20161.10m0.16%
More ▼
Data from 30 Jun 2016 - 31 Mar 2017Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.